Goethe University Frankfurt-ko ikertzaileekin lankidetzan egindako argitalpenak (7)

2021

  1. Adjunctive Volasertib in Patients with Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial

    HemaSphere, Vol. 5, Núm. 8, pp. E617

2020

  1. Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia

    Blood, Vol. 135, Núm. 5, pp. 371-380

2011

  1. The European Leukemianet: Achievements and perspectives

    Haematologica, Vol. 96, Núm. 1, pp. 156-162

2006

  1. Long-term survival data from a phase 3 study of Filgrastim as an adjunct to chemotherapy in adults with de novo acute myeloid leukemia

    Leukemia, Vol. 20, Núm. 3, pp. 404-409

2003

  1. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

    Blood, Vol. 102, Núm. 8, pp. 3043-3051

  2. Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia - A randomized, placebo-controlled, double-blind safety and efficacy study

    Annals of Hematology, Vol. 82, Núm. 11, pp. 677-683

2002

  1. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia

    Blood, Vol. 100, Núm. 12, pp. 3877-3886